Alnylam Pharmaceuticals (ALNY) Tax Provisions (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has 14 years of Tax Provisions data on file, last reported at $13.3 million in Q2 2026.

• Quarterly Tax Provisions fell 56.95% year-over-year to $13.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$8.4 million (up 86.07% YoY) and the FY2025 annual result came in at $9.4 million, up 109.48% from the prior year.
• Tax Provisions slipped to $13.3 million in Q2 2026, from $15.7 million in the prior quarter.
• In the past five years, Tax Provisions ranged from a high of $30.9 million in Q2 2025 to a low of -$110.2 million in Q4 2024.
• A 5-year average of -$2.8 million and a median of $2.1 million in 2023 frame the typical range for Tax Provisions.
• Annual changes were most pronounced in 2023 — Tax Provisions soared 13091.3% — and 2024, when it tumbled 60315.85%.
• Tracing ALNY's Tax Provisions over 5 years: stood at $472000.0 in 2022, then slumped by 61.23% to $183000.0 in 2023, then plunged by 60315.85% to -$110.2 million in 2024, then jumped by 77.06% to -$25.3 million in 2025, then soared by 152.65% to $13.3 million in 2026.
• The last three Tax Provisions figures came in at $13.3 million (Q2 2026), $15.7 million (Q1 2026), and -$25.3 million (Q4 2025), per Business Quant data.